Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial ; volume:30 ; number:7 ; day:25 ; month:5 ; year:2024 ; pages:2058-2066 ; date:7.2024
Nature medicine ; 30, Heft 7 (25.5.2024), 2058-2066, 7.2024
- Creator
-
Colhoun, Helen M.
Lingvay, Ildiko
Brown, Paul M.
Deanfield, John
Brown-Frandsen, Kirstine
Kahn, Steven E.
Plutzky, Jorge
Node, Koichi
Parkhomenko, Alexander
Rydén, Lars
Wilding, John P. H.
Mann, Johannes F. E.
Tuttle, Katherine R.
Idorn, Thomas
Rathor, Naveen
Lincoff, A. Michael
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41591-024-03015-5
- URN
-
urn:nbn:de:101:1-2410052109110.296605304841
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Colhoun, Helen M.
- Lingvay, Ildiko
- Brown, Paul M.
- Deanfield, John
- Brown-Frandsen, Kirstine
- Kahn, Steven E.
- Plutzky, Jorge
- Node, Koichi
- Parkhomenko, Alexander
- Rydén, Lars
- Wilding, John P. H.
- Mann, Johannes F. E.
- Tuttle, Katherine R.
- Idorn, Thomas
- Rathor, Naveen
- Lincoff, A. Michael
- SpringerLink (Online service)
Other Objects (12)
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Semaglutide in Obesity: Unmet Needs in Men
US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events
Semaglutide
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
Semaglutide treatment of hypothalamic obesity – a real-life data study
Oral semaglutide in kidney transplant recipients with metabolic syndrome: three Japanese cases
Cardiovascular risk and obesity
Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Semaglutide in Obesity: Unmet Needs in Men
US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events
Semaglutide
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
Semaglutide treatment of hypothalamic obesity – a real-life data study
Oral semaglutide in kidney transplant recipients with metabolic syndrome: three Japanese cases
Cardiovascular risk and obesity
Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Semaglutide in Obesity: Unmet Needs in Men
US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events
Semaglutide
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
Semaglutide treatment of hypothalamic obesity – a real-life data study
Oral semaglutide in kidney transplant recipients with metabolic syndrome: three Japanese cases
Cardiovascular risk and obesity
Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction